Equity Research Medical Devices

Should You Buy Accuray Incorporated Stock in 2026?

By CirclFi Research Team · · Updated · 1/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Accuray Incorporated (ARAY) carries a solid Quality of Company rating of 6.4/10. Trading at $0.26, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.

The short answer: 0 of 1 CirclFi valuation models project upside for Accuray Incorporated (ARAY) at $0.26 — the model consensus leans bearish, with a Quality Score of 6.4/10 and Value-Trap risk of 26/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 1 of 1 models suggest overvaluation — majority bearish
  • Quality Score: 6.4/10 — Moderate — mixed signals
  • Value Trap Risk: 26/100 — Low — manageable risk
  • Fair Value Range: $0.25 – $0.25 (0% spread)

Bullish Models

0 / 1

Bearish Models

1 / 1

Quality Score

6.4 /10

Moderate — mixed signals

Value Trap Risk

26 /100
Low

Low — manageable risk

Model Consensus

1 /13
Active Models

Avg. confidence: 62%

What Is the Investment Case for Accuray Incorporated (ARAY) in 2026?

What Is the Bull Case vs the Bear Case for Accuray Incorporated (ARAY)?

Bull case versus bear case for Accuray Incorporated (ARAY) at $0.26, derived from 1 active CirclFi valuation models on 2026-10-07.
Bull case Bear case — $0.25 target (-5.1%)
No active model projects meaningful upside for ARAY at $0.26. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. Industry headwind: generic/biosimilar competition represents a meaningful risk for Accuray Incorporated and its Medical Devices peers.

How Does ARAY Compare to Its Medical Devices Peers?

BFLY Butterfly Network, I
6.4
ECOR electroCore, Inc.
6.4
RDGL Vivos Inc.
6.4
APYX Apyx Medical Corpora
6.3
TNDM Tandem Diabetes Care
6.5
PETV PetVivo Holdings, In
6.3
GTHP Guided Therapeutics,
5.5
GCTK GlucoTrack, Inc.
3.5

Valuation data pages: BFLY · ECOR · RDGL · APYX · TNDM · PETV · GTHP · GCTK · BRKR · IRMD · PODD

See full Medical Devices rankings →

Which Other Stocks Score Like ARAY on Quality?

Closest companies to ARAY’s Quality of Company score of 6.4/10, across all industries.

Which Medical Devices Screens Does ARAY Appear In?

Why Do CirclFi’s 1 Models Disagree on ARAY?

Spread

0%

Fair Value Range

$0.25 – $0.25

A tight 0% spread suggests meaningful convergence, strengthening conviction in the composite estimate.

Most Bullish

ML-RIV

$0.25 (-5.1%)

Most Bearish

ML-RIV

$0.25 (-5.1%)

What Are the Biggest Risks of Buying ARAY Stock?

Bearish Consensus

1/1 models suggest overvaluation.

Macro/Sector Risk

Medical Devices headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View ARAY Data Page →

So Is Accuray Incorporated (ARAY) Worth Buying in 2026?

Our valuation engine sends a clear cautionary signal on Accuray Incorporated at $0.26. 1/1 models flag overvaluation, median fair value sits at $0.25 (-5.1%), and the risk-reward profile appears unfavorable. Quality at 6.4/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.

These are quantitative model outputs, not investment recommendations. Accuray Incorporated's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

What Else Do Investors Ask About ARAY Stock?

Should I buy ARAY stock right now?

Based on CirclFi's multi-model analysis, 0 of 1 models see upside for ARAY at $0.26. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Accuray Incorporated?

Key risks include: limited model coverage (1/13 active), reducing analytical confidence; general market and sector-specific risks affecting Medical Devices companies. Always diversify and consult a financial advisor.

How does ARAY compare to its competitors?

Among Medical Devices peers, ARAY holds a Quality Score of 6.4/10. Comparable companies include BFLY (QOC 6.4), ECOR (QOC 6.4), RDGL (QOC 6.4). The relative ranking helps investors identify whether ARAY offers better fundamental quality than alternatives in the same sector.

Is ARAY a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. ARAY's Quality Score of 6.4/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.

What price should I buy ARAY at?

CirclFi does not provide target buy prices or price alerts. However, our 1 active models produce fair value estimates ranging from $0.25 to $0.25. At $0.26, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for ARAY.

View ARAY Data Page Full Terminal — $60/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →